An ongoing dialogue on HIV/AIDS, infectious diseases,
November 30th, 2008
How to End the HIV Epidemic
Answer: Put everyone on treatment.
Conspicuously absent for decades, the prevention part of the “when to start antiviral therapy?” question has now moved front and center in two recent papers:
- In this week’s Lancet, a group from the WHO estimated what would happen if there were annual universal HIV testing, and then immediate treatment for all found to be positive. They used South Africa — the country with the highest number of HIV cases — as a test case, and assumed heterosexual transmission of HIV. After going through the usual gyrations required in such mathematical models, they found that such a treat-everyone strategy would shift the HIV epidemic in South Africa from its current (dismal) phase to an “elimination phase” — with an ending to the epidemic feasible by 2020.
- This summer, researchers from Vancouver (of course from their Excellent “Centre for Excellence”) published a paper with largely similar findings — this time applied to an epidemic that is more typical of developed countries, predominantly made up of gay men and injection drug users. As with the WHO/South Africa paper, there would be a high up-front cost of expanding therapy, but ultimately costs would be lower because of averted infections.
The treatment-as-prevention theme, of course, got off to a roaring start this year when the Swiss National AIDS Commission issued a statement saying that people with HIV who are adherent to antiretroviral therapy, have undetectable plasma viral loads, and have no sexually transmitted infections are not infectious to others.
Very bold — especially for a country famous for chocolate, watches, and fondue.
While the certainty of this statement struck some as extreme, and others as bordering on arrogant — and this single case report is an example of how doctors should “never say never” — the principle behind the Swiss statement was sound, and quite helpful in getting the conversation started. Treatment can be prevention, and this is something we should discuss with each of our patients when reviewing the pros and cons of going on therapy.
Categories: Health Care, HIV, Infectious Diseases, Patient Care, Policy
Tags: antiretroviral therapy, epidemiology, health care policy, HIV, Policy, prevention, transmission
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “How to End the HIV Epidemic”
Paul E. Sax, MD
NEJM Journal Watch
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Really Rapid Review — CROI 2023, Seattle
- Oral Antibiotic Therapy for Endocarditis — Are We There Yet?
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Medical Masks vs. N95 Respirators for Preventing COVID-19 Among Healthcare Workers
- Interferon Lambda for COVID-19 — Looking Good, but Still Not Available
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
NEJM Journal Watch — Recent Infectious Disease Articles
- Higher COVID-19 Testing Rates for Nursing Home Staff Are Associated with Fewer Resident Infections and Deaths
- PrEP with Tenofovir/Emtricitabine: Safe During Pregnancy
- TB Therapy: How Short Can We Go?
- Cluster of Post–Cardiac Surgery Mycobacterial Infections — Something About the Water?
- Adding Ceftriaxone to Daptomycin for Managing Streptococcus mitis-oralis Endocarditis
- 3tc Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
Most HIV/AIDS patients that I have had the opportunity to meet with here in the US, have superior knowledge about their disease. They scourge the internet and read up anything they see about their medication, and possible “new cures”
Most of these patients too have gone to great lengths to keep their virus suppressed, borne the brunt of varied side-effects, and have kept the faith.
Reading these essays (published) about use and non use of condoms, I will advocate more care and rigor before sending out publications out to the mad world of the net. Many HIV/AIDs people are waiting for the great new cure ……magic bullet……and they might be tempted to go with the tide of new findings before they are validated.
i hope the this is a sure cure. this guys really need help. just imagine you love one dieing in you hands not because the money isnt there but because there is no solution. it kills the reason to live.